NSETrading Window26 Jun 2026 · 26 Jun 2026, 03:48 pm

Trading Window

Senores Pharmaceuticals Limited · SENORES

✦ AI SummaryRegulatory

Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of unaudited financial results for the quarter ending June 30, 2026.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk3/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

SENORES_26062026154814_Intimationregardingclosureoftradingwindowsigned.pdf

pdf

Download →
View document text
Date: June 26, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Dear Sir/Madam, Subject: Intimation of Trading Window Closure Pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“SEBI PIT Regulations”) as amended from time to time and Company's Code of Conduct (“Code”) for prevention of insider trading, the trading window, for trading in the securities of the Company by the Directors, Promoters, Designated Persons and their immediate relatives, shall remain closed from July 01, 2026 till 48 hours after announcement / declaration of Unaudited Financial Results for quarter ending on June 30, 2026. In view of the above, all the Directors, Promoters, Designated Persons and their immediate relatives are advised not to trade in the securities of the Company during the aforesaid period of closure of trading window. The date of Board Meeting for approving the Unaudited Financial Results for quarter ending on June 30, 2026, will be intimated separately in due course. You are requested to take the same on record and acknowledge the receipt of the same. Thanking you. For Senores Pharmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263